Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL: camrelizumab plus chemotherapy and local consolidation therapy for first-line oligometastatic NSCLC with PD-L1 <50%
ChiCTR2500099469Phase 2Not yet recruiting
- Sponsor
- Guangzhou Panyu District Central Hospital
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Panyu District Central Hospital. Primary endpoint: Progression-Free Survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099469.